# Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

> **NCT03050450** · PHASE1 · TERMINATED · sponsor: **Johns Hopkins All Children's Hospital** · enrollment: 8 (actual)

## Conditions studied

- Central Nervous System Tumors

## Interventions

- **DRUG:** 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- **DRUG:** 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- **DRUG:** 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- **DRUG:** 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- **DRUG:** 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)

## Key facts

- **NCT ID:** NCT03050450
- **Lead sponsor:** Johns Hopkins All Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-10
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Lack of feasibility to accrue patients in allotted time.
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050450, "Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03050450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*